Stay updated with breaking news from Kodiak Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) has been assigned a consensus recommendation of “Reduce” from the six research firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and one has assigned a buy recommendation to the […]
Shares of Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) have been given an average recommendation of “Reduce” by the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating […]
The Goldman Sachs Group reaffirmed their sell rating on shares of Kodiak Sciences (NASDAQ:KOD – Free Report) in a research note published on Monday, MarketBeat reports. The Goldman Sachs Group currently has a $2.00 price target on the stock. Separately, Capital One Financial raised Kodiak Sciences from an equal weight rating to an overweight rating […]
TODAY’S GAME PLAN: from the trading desk, this is not research DATA/HEADLINES 11:00ET NY Fed 1-Yr Inflation Expectations; 11:30ET 3 Year Note Auction; 1:00ET 10 Year Note Auction Tuesday: Japan producer prices, India inflation, Brazil inflation, UK unemployment, US inflation TODAY’S HIGHLIGHTS: Zelenskiy travels to the US to discuss Ukraine’s urgent defense needs with President
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.